Diversify Advisory Services LLC Has $2.53 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Diversify Advisory Services LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 24.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,266 shares of the company's stock after buying an additional 3,219 shares during the quarter. Diversify Advisory Services LLC's holdings in Zoetis were worth $2,528,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of Zoetis in the 4th quarter valued at $824,321,000. Wellington Management Group LLP grew its holdings in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after acquiring an additional 3,059,255 shares in the last quarter. Sarasin & Partners LLP bought a new position in shares of Zoetis in the 1st quarter valued at about $339,111,000. GAMMA Investing LLC grew its holdings in shares of Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after acquiring an additional 1,747,423 shares in the last quarter. Finally, Capital Research Global Investors bought a new position in shares of Zoetis in the 4th quarter valued at about $178,688,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Down 0.2%

Shares of NYSE:ZTS traded down $0.34 during mid-day trading on Friday, reaching $149.19. 663,472 shares of the company's stock were exchanged, compared to its average volume of 2,603,176. The firm has a market capitalization of $66.42 billion, a price-to-earnings ratio of 26.80, a PEG ratio of 2.51 and a beta of 0.91. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The business's fifty day moving average price is $161.00 and its 200-day moving average price is $161.54.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the business posted $1.38 EPS. The firm's revenue was up 1.4% compared to the same quarter last year. On average, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is currently 35.91%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ZTS. UBS Group decreased their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the company from $180.00 to $155.00 in a research note on Thursday. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $204.63.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.